UNSPSC 51181553: Minalrestat

This classification denotes an aldose reductase inhibitor with the molecular formula C19H11BrF2N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G44PE6QB31, chemically known as 2-((4-bromo-2-fluorophenyl)methyl)-6-fluorospiro(isoquinoline-4(1h),3-pyrrolidine)-1,2,3,5(2h)-tetrone but generally known as minalrestat, which bears US NIH Compound Identifier 190816. European Medicines Agency schedules Minalrestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08972MIG.

UNSPSC 51181553 Minalrestat is a Commodity code for a specific pharmaceutical active ingredient, but state and local procurement under this code actually targets generic multi-source pharmaceuticals and over-the-counter products distributed across government health and social-service facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, operates as the primary issuing body, leveraging cooperative purchasing to aggregate demand across multiple participating states and local jurisdictions. Vendors supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with products required to meet current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance. Evaluation emphasizes price competitiveness (75 percent weight), with secondary scoring on fixed pricing (10 percent), administrative fee format compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must carry commercial general liability of $5,000,000 per occurrence and maintain contractual relationships with at least two of the three authorized wholesalers.

MMCAP's January 20, 2026 RFP for Generic Multi Source Pharmaceuticals and OTC Products (due March 26, 2026) represents the primary recent activity under this code, with participation from Minnesota, Oregon, and other cooperative member jurisdictions. The procurement seeks manufacturers to provide National Drug Code (NDC)-specific pricing and product information; all products must be available in the marketplace by May 15, 2026, with awarded vendor agreements effective July 1, 2026. Contract terms run two years for new responders with optional MMCAP extensions, while incumbent amendments align with existing expiration dates through June 30, 2028. The RFP does not identify specific dollar ranges, but vendors should anticipate performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding deadlines, or improper class-of-trade denials. Questions close February 18, 2026.